Patients taking the hypertension treatment irbesartan/hydrochlorothiazide could be at risk of an overdose because of a printing error on some of the patient information leaflets, the MHRA has warned.

The leaflet for Teva UK's irbesartan/hydrochlorothiazide 300/12.5mg and 300/25mg incorrectly states a dose of one or two tablets a day instead of the recommended dose of once a day, the MHRA said on Wednesday (January 8).

Teva had stopped the distribution of the affected batches but they would remain in pharmacies for a "short period of time" to avoid shortage issues, the MHRA added.

Anyone seeking medical information on the drug can contact Teva UK Ltd on 020 7540 7117 or email [email protected].